How do you decide whether to offer tamoxifen or OFS + AI in premenopausal patients with metastatic ER+ HER2+ breast cancer as your endocrine therapy?

Topics: Breast Cancer • Medical Oncology • Her2+ • HR+ • Breast Cancer, Non-metastatic

What data may support the routine escalation of endocrine therapy? Should HER2 therapy be prioritized instead?

Answer from: Medical Oncologist at Community Practice

In general, for node-positive premenopausal women, I use AI and OS. For node-negative patients, I generally use tam + OS for oncotypes 16-21 (the group where we saw a 2% benefit from chemo in TAILORx) and AI + OS for oncotypes 21-25 (where we saw a 7% benefit from chemo in TAILORx). It seems from SO...

Comments

Medical Oncologist at PeaceHealth
I thought the question was about metastatic breast...

Related Questions